Horizons Hémato – Vol. 13 n°3 – Septembre 2023
You don't have permission to view the content
You don't have permission to view the content
La prise en charge des patients présentant un lymphome de Hodgkin a significativement changé ces 5 dernières années sur la base des résultats de nombreux essais de phase III et de la disponibilité de nouvelles classes thérapeutiques qui ont changé le pronostic des patients en échec de la chimiothérapie et/ou de la radiothérapie. Le LYSA (LYmphoma [...]
You don't have permission to view the content
You don't have permission to view the content
You don't have permission to view the content
You don't have permission to view the content
You don't have permission to view the content
You don't have permission to view the content
You don't have permission to view the content
You don't have permission to view the content